Takeda Pharmaceutical Company Limited

The University of Manchester

St Georges Hospital Medical School

St George's Hosptial Medical School

Domainex Limited

Kerry Jenkins

Martin Teall

Natasha Kinsella

Anne Goldby

Trevor Robert Perrior

Mark Richard Stewart

Gary Karl Newton

Clive Robinson

Sarah Bousba

Jihui Zhang

David Ronald Garrod

Meriel Ruth Major

David Livermore

Richard John Davenport

Rebekah Elisabeth Key

Susanne Wright

David Harrison

Hannah Canning

Saleh Ahmed

Anna Hopkins

Gregory Barker

Rebekah Elisabeth Beevers

Gabriel Negoita-giras

Stuart Richard Crosby

Meriel Ruth Mayor

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, in which R, R, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. 

Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, X, X, Y, Y, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Compounds

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy. 

Piperidine and azepine derivatives as prokineticin receptor modulators

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. 

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as 'PVA compounds'), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy. 

Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use

The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as 'PVA compounds'), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

Growing community of inventors

Cambridge, United Kingdom

Kerry Jenkins